PsA ACR RESPONDER RATES

Durable improvements in joint pain and stiffness through 4 years, NRI1,5,32

Study: RAPID-PsA1,10a

Primary Endpoint

 
 
 

RAPID-PsA ACR20 responder rates through 4 years1,10,32b

The same patients may not have responded at each time point

 

Placebo rates at Week 241,10

– ACR20: 24%
– ACR50: 13%
– ACR70: 4%
 

The ACR response criteria assess changes in swollen and tender joints, pain, functional ability, patient and physician assessment, and acute phase reactant33

 

Limitation of OLE: ACR Responder Rates do not have long-term placebo comparator beyond Week 2432

  1. RS-NRI: randomized set nonresponder imputation.
  2. Line graph to Week 216 represents patients who were randomized initially to CIMZIA 200 mg Q2W.

ACR, American College of Rheumatology; NRI, nonresponder imputation; PsA, psoriatic arthritis; Q2W, every 2 weeks.

CIMZIA inhibited radiographic progression compared to placebo at Week 241a

expandcollapse

8 out of 10 x-rayed patients receiving CIMZIA 200 mg Q2W experienced no radiographic progression over 4 years (n=98)32b

Patients treated with CIMZIA 400 mg Q4W did not demonstrate greater inhibition of radiographic progression compared with placebo-treated patients at Week 241

  1. For placebo patients who escaped early to CIMZIA, the Week 24 values were linearly extrapolated. The P value of CIMZIA vs placebo is based on analysis of covariance. For patients with 2 radiographs but a missing Week 24 or baseline film, linear extrapolation was performed in all approaches.
  2. Limitation of 4 year data: Open label extension does not have a placebo control arm. ‘No progression’ was defined as a change from baseline in mTSS of ≤0.5. When ‘no progression’ was defined as a change from baseline in mTSS of ≤0, 63.3% of x-rayed patients experienced no progression.

mTSS, modified Total Sharp Score; Q2W, every 2 weeks; Q4W, every 4 weeks.